The boosters target the omicron BA.1 sublineage.
Assuming the European Commission follows CHMP’s recommendations, the European vaccine campaign will use bivalent vaccines targeting the original version of the omicron variant.
U.S. regulators, by contrast, have backed the use of bivalent vaccine boosters that target the BA.4/BA.5 sublineages of omicron. While Pfizer/BioNTech (NYSE:/PFE, Nasdaq: BNTX) and Moderna (Nasdaq:MRNA) have both developed vaccine boosters based on BA.4/BA.5, there is currently no human data for those vaccines. Instead, FDA is relying on data from earlier vaccine versions and preclinical data.
EMA’s recommended that the updated boosters be used in individuals at least 12 years of age who have…